Adam S. Fang

Dr. Adam S. Fang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2021 in Seminars in Interventional Radiology
Verified
Journal Article
Closed access
PDF file
AFAdam S. Fang
Adam S. Fang
IKIl Kyoon Kim
Il Kyoon Kim
IUIfechi Ukeh
Ifechi Ukeh
VEVahid Etezadi
Vahid Etezadi
HKHyun S. Kim
Hyun S. Kim
Benign biliary strictures are often due to a variety of etiologies, most of which are iatrogenic. Clinical presentation can vary from asymptomatic disease with elevated liver enzymes to obstructive jaundice and recurrent cholangitis. Diagnostic imaging methods, such as ultrasound, multidetector computed tomography, and magnetic resonance imaging (cholangiopancreatography), are used to identify stricture location, extent, and possible source of biliary obstruction. The management of benign biliary strictures requires a multidisciplinary team approach and include endoscopic, percutaneous, and surgical interventions. Percutaneous biliary interventions provide an alternative diagnostic and therapeutic approach, especially in patients who are not amenable to endoscopic evaluation. This review provides an overview of benign biliary strictures and percutaneous management by interventional radiologists. Diagnostic evaluation with percutaneous transhepatic cholangiography and treatment options, including biliary drainage, balloon dilation, retrievable/biodegradable stents, and other innovative minimally invasive options, are discussed.

1 February 2016 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
AFAdam S. Fang
Adam S. Fang
LMLalita Movva
Lalita Movva
SAShah Ahmed
Shah Ahmed
DWDavid Waldman
David Waldman
JXJingbing Xue
Jingbing Xue

30 June 2023 in Life
Verified
Journal Article
Open access
PDF file
CSChang Shu
Chang Shu
MLMaria Lim
Maria Lim
AFAdam S. Fang
Adam S. Fang
Soft tissue tumors (STTs) include a range of benign and malignant tumors originating from soft tissues. Transarterial and percutaneous therapies are image-guided and minimally invasive approaches for managing primary and metastatic STTs. The objective of this review is to discuss transarterial and percutaneous therapies by examining the current literature, including indications, patient selection, safety, and effectiveness. Transarterial therapies (e.g., transarterial bland embolization and transarterial chemoembolization) involve the delivery of either embolic or chemotherapeutic particles using a catheter into arteries feeding the tumor, resulting in localized tumor destruction. Percutaneous therapies (e.g., radiofrequency ablation, cryoablation, irreversible electroporation, laser ablation, and magnetic resonance-guided high-intensity focused ultrasound) involve the delivery of either hot or cold temperatures, electrical current, laser, or ultrasound to specifically target tumor cells. Both therapies have been shown to be safe and effective for reducing morbidity and local control of STTs, specifically in patients who are surgically inoperable or who are unresponsive to conventional therapies. Accurate diagnosis, staging, and histological subtype identification are crucial for treatment selection. A multidisciplinary approach, a thorough understanding of tissue anatomy and surrounding structures, as well as individualized strategies based on assessment are essential for optimal patient care.

12 January 2021 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Closed access
PDF file
SSSheetal Sethupathi
Sheetal Sethupathi
KWKate Walter
Kate Walter
MLMaria Lim
Maria Lim
AFAdam S. Fang
Adam S. Fang

25 April 2023 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
FRFernando Rivera-Melendez
Fernando Rivera-Melendez
AFAdam S. Fang
Adam S. Fang

1 October 2023 in Seminars in Interventional Radiology
Verified
Journal Article
Closed access
PDF file
TGTushar Garg
Tushar Garg
FKFereshteh Khorshidi
Fereshteh Khorshidi
Peiman HabibollahiPeiman Habibollahi
Peiman Habibollahi
ASApurva Shrigiriwar
Apurva Shrigiriwar
AFAdam S. Fang
Adam S. Fang
Nariman NezamiNariman Nezami
Nariman Nezami
Acute gastrointestinal bleeding (acute GIB) is a major cause of mortality and morbidity in patients despite various advances in diagnosis and treatment. In the United States, around 390,000 patients are admitted with acute GIB annually, and mortality rates range from 3 to 8.8%.[1] The presentation of these patients can vary from minor, self-limited bleeding that can be managed in outpatient settings to life-threatening bleeding that requires aggressive resuscitation and emergent intervention.[1] Early and accurate diagnosis followed by prompt and appropriate treatment is imperative in the management of acute GIB. In this review, we will discuss the epidemiology, presentation, diagnosis, and management of acute GIB, with particular focus on diagnostic imaging and endovascular management. GIB is usually categorized on the basis of the location and severity of the bleeding. Upper GIB (UGIB) originates between the esophagus and the ligament of Treitz, whereas lower GIB (LGIB) occurs in the small bowel distal to the ligament of Treitz, the colon, or the rectum.[1] In 75 to 85% of GIB cases, the source of hemorrhage is in the upper gastrointestinal tract.[2] The annual incidence of UGIB is around 50 to 100 per 100,000 population, and the median age of patients is 60 to 70 years.[3] The mortality rate in these patients is between 3 and 14%, and this increases to 43 to 64% in patients who need intensive care.[4] The most common causes of UGIB are peptic ulcer disease, esophagogastric varices, and erosive esophagitis; other less common causes are bleeding from esophageal or gastric tumors, Mallory–Weiss syndrome, reflux esophagitis, angiodysplasia, and iatrogenic or posttraumatic changes.[5] This review does not focus on the management of variceal bleeding, even though it is a common and important cause of GIB, as the diagnostic and interventional approach differs between variceal and nonvariceal bleeding. Around 33 to 87 per 100,000 population are hospitalized because of LGIB annually, with mortality rates ranging from 2.5 to 3.9% and rebleeding occurring within a year in 13 to 19% of these individuals . Compared to UGIB, there are fewer effective methods for preventing the recurrence of LGIB.[3] [6] [7] [8] [9] [10] [11] In patients with LGIB, determining the source of the bleeding and its severity is crucial in managing patients. The causes of LGIB can be anatomic, vascular, inflammatory, or neoplastic. Diverticulosis has been found to be the most common cause, accounting for 15 to 55% of LGIB cases; however, angiodysplasia is the most common cause of LGIB in individuals over the age of 65 years.[12] [13] Article published online: 02 November 2023 © 2023. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA